To determine the underlying causes of neuronal vulnerability at the earliest stages of Alzheimer's Disease (AD), a research ...

Alzheimer’s disease is characterized by a host of recognizable cognitive symptoms, but many non-cognitive symptoms like changes in sleep, anxiety and depression can be early signs of the disease.

The presented trial results, especially in MCI patients, are promising, particularly as Alzheon is targeting a subset of ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s ...

Detailed price information for Acumen Pharmaceuticals Inc (ABOS-Q) from The Globe and Mail including charting and trades.

A consequence of this is that toxic amyloid-beta oligomers (small clumps of amyloid-beta protein) may "sneak in" to the neurons via this same receptor. Conversely, the SN expresses a selective ...

PMN310 is uniquely designed to selectively target toxic oligomers of amyloid-beta, which we believe is a key differentiator from both approved treatments and those currently in development.

ProMIS Neurosciences (PMN) announced plans to deliver virtual oral presentations at the 2025 Alzheimer’s and Parkison’s Disease International ...

Alzinova AB (publ) (ticker: ALZ) today announces that the final analysis of data from the Phase 1b clinical study with the vaccine candidate ALZ-101, which included patients with early Alzheimer's dis ...